Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ...

J&J's Imaavy (nipocalimab-aahu) has received US Food and Drug Administration (FDA) approval for treating generalised ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

Amsterdam, the Netherlands Tuesday, April 29, 2025, 10:00 Hrs [IST] ...

University of Miami Miller School of Medicine researchers have identified molecular evidence linking human papillomavirus ...

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.

A mother gives her baby immunity even before birth. Vaccines during pregnancy protect both, boosting the baby's defense ...